The Longevity Fund
Status
ACTIVE
Global HQ
San Francisco, United States
Countries of investment
- USA
Investment stages
- Pre-Seed
- Seed
- Series A
- Series B
Industries
- Health Tech
- Biotechnology
- AI
- Data science
About
The Longevity Fund, founded by Laura Deming in 2011, focuses on investing in biotechnology and health tech companies that aim to develop drugs and technologies to extend healthy human lifespan. The fund has supported some of the pioneering companies in this space, helping them to IPO and bring drug candidates into clinical trials for agerelated diseases. They believe in the potential of unconventional and missiondriven founders to lead the field, advocating for a new generation of founders who can think differently about regulatory, scientific, fundraising, and companybuilding strategies. The Longevity Fund is now launching a new fund with a new name, with a continued commitment to advancing longevity science and medicine.
The Longevity Fund, founded by Laura Deming in 2011, focuses on investing in biotechnology and health tech companies that aim to develop drugs and technologies to extend healthy human lifespan. The fund has supported some of the pioneering companies in this space, helping them to IPO and bring drug candidates into clinical trials for agerelated diseases. They believe in the potential of unconventional and missiondriven founders to lead the field, advocating for a new generation of founders who can think differently about regulatory, scientific, fundraising, and companybuilding strategies. The Longevity Fund is now launching a new fund with a new name, with a continued commitment to advancing longevity science and medicine.
Investment Thesis
The Longevity Fund aims to invest in companies developing drugs and technologies to extend healthy human lifespan.